Original Article

Community-Acquired Pneumonia with Risk for Drug-Resistant Pathogens

Authors: Virginia Fleming, PharmD, BCPS, Brian Buck, PharmD, FASHP, Nancy Nix, PharmD, Parag Kumar, PharmD, Robin Southwood, PharmD, BCPS

Abstract

Background: Pneumonia is a leading infectious cause of morbidity and mortality in the United States. The Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) have published treatment guidelines for community-acquired pneumonia (CAP) based upon the site of acquisition and specific pathogen risk. The literature demonstrates improved outcomes with guideline-concordant empiric therapy. A subset of patients with CAP has risk factors for drug-resistant pathogens (DRPs). IDSA/ATS treatment guidelines do not provide clear recommendations for empiric treatment, and clinical studies have not provided descriptive data for this group.


Methods: A retrospective chart review of all admissions between January 1, 2008 and April 19, 2009 with an International Classification of Diseases-9 code and physician-documented diagnosis of pneumonia at two community hospitals were performed. IDSA pneumonia type and presence of risk factors for DRP were recorded for each patient, and the empiric antibiotic therapy received was evaluated. Admissions were excluded if immunosuppression or pregnancy was present.


Results: Of the 400 admissions reviewed, 343 patients were included. A total of 228 patients (71%) had CAP. Forty-three percent of patients with CAP had risk factors for DRP. Only 2% of this group received an antibiotic regimen with coverage of the specific DRP risk factor present. The most common DRPs not receiving coverage in this group were Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. P. aeruginosa and methicillin-resistant S. aureus occurred more commonly in culture-positive patients with CAP with DRP risk factors but did not achieve statistical significance. A larger sample size would be needed to determine whether this difference is significant.


Conclusions: Risk factors for DRP occurred commonly in our CAP population. Patients with CAP with risk for DRP may be a distinct group who are without clear guidance on treatment. Future studies are needed to define the risk of DRP and the impact upon empiric therapy for patients with CAP.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hall MJ, DeFrances CJ, Williams SN, et al. National Health Statistics Reports. National Hospital Discharge Survey: 2007 summary. http://www.cdc.gov/nchs/data/nhsr/nhsr029.pdf. Accessed August 29, 2011.
 
2. Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007. http://www.cdc.gov/NCHS/data/nvsr/nvsr58/nvsr58_19.pdf. Accessed August 29, 2011.
 
3. Centers for Disease Control and Prevention, National Center for Health Statistics. Health data interactive. Mortality by underlying cause, ages 18+: US/state, 2001–2009. http://205.207.175.93/HDI/TableViewer/tableView.aspx?ReportId=673. Accessed October 19, 2012.
 
4. Centers for Disease Control and Prevention. National Center for Health Statistics. Health data interactive. Emergency department visits: US, 1995–2009. http://205.207.175.93/HDI/TableViewer/tableView.aspx?ReportId=113. Accessed July 20, 2011.
 
5. File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122: 130–141.
 
6. Dean NC, Bateman KA, Donnelly SM, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006; 130: 794–799.
 
7. Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39: 955–963.
 
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27–S72.
 
9. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416.
 
10. McCabe C, Kirchner C, Zhang HL, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia playing by the rules. Arch Intern Med 2009; 169: 1525–1531.
 
11. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010; 32: 293–299.
 
12. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169: 1515–1524.
 
13. Grenier C, Pepin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011; 66: 1617–1624.
 
14. Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 2008; 47: S193–S201.
 
15. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002; 162: 682–688.
 
16. Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726–731.
 
17. Mortensen EM, Restrepo MI, Anzueto A, et al. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006; 119: 859–864.
 
18. Frei CR, Restrepo MI, Mortensen EM, et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006; 119: 865–871.
 
19. Asadi L, Eurich DT, Gamble JM, et al. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012; 106: 451–458.
 
20. Silveira CD, Ferreira CS, Correa R. Adherence to guidelines and its impact on outcomes in patients hospitalized with community-acquired pneumonia at a university hospital. J Bras Pneumol 2012; 38: 148–157.
 
21. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011; 38: 878–887.
 
22. El Solh AA, Akinnusi ME, Alfarah Z, et al. Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing home-acquired pneumonia. J Am Geriatr Soc 2009; 57: 1030–1035.
 
23. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54: 470–478.
 
24. Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54: 193–198.
 
25. Madaras-Kelly KJ, Remington RE, Fan VS, et al. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med 2012; 7: 195–202.
 
26. Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010; 137: 1283–1288.
 
27. Labelle AJ, Arnold H, Reichley RM, et al. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 2010; 137: 1130–1137.
 
28. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347–382.
 
29. Shorr AF, Zilberberg MD, Micek ST, et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Inter Med 2008; 168: 2205–2210.